
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
Novartis has signed an aggreement contracting Cryoport-provider of logistics solutions for biopharmaceutical, IVF, and animal health organizations globally-over an initial three-year tern for cryogenic logistics support of CTL019/CD19 CAR-T cell therapy.
Read the full release






